Aldeyra Therapeutics Inc (NASDAQ:ALDX) traded down 5.1% during mid-day trading on Wednesday . The company traded as low as $5.37 and last traded at $5.43, with a volume of 54,044 shares changing hands. The stock had previously closed at $5.72.

A number of equities research analysts have issued reports on the stock. Stifel Nicolaus assumed coverage on shares of Aldeyra Therapeutics in a report on Friday, July 1st. They set a “buy” rating and a $16.00 price objective for the company. Cowen and Company reaffirmed a “buy” rating on shares of Aldeyra Therapeutics in a report on Tuesday, May 10th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Aldeyra Therapeutics currently has an average rating of “Buy” and a consensus target price of $13.15.

The stock’s market capitalization is $34.60 million. The company’s 50-day moving average price is $5.80 and its 200-day moving average price is $5.38.

Aldeyra Therapeutics (NASDAQ:ALDX) last released its earnings results on Wednesday, August 10th. The biotechnology company reported ($0.41) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.44) by $0.03. Analysts predict that Aldeyra Therapeutics Inc will post ($1.69) earnings per share for the current fiscal year.

Aldeyra Therapeutics, Inc, formerly Aldexa Therapeutics, Inc, is a biotechnology company. The Company is focused primarily on the development of new products for immune-mediated, inflammatory, orphan and other diseases that are caused by naturally occurring toxic chemical species known as free aldehydes.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.